GLP-1 receptor agonists · Diabetes & weight management

Clara reads your full chart before matching you to the right GLP-1.

Clara reads your A1C, your BMI trend, your weight-related comorbidities, and your medication list, then drafts the on-label brand for your indication. A physician signs off on every Rx.

Get started How it works

GLP-1 candidacy · pre-prescription chart read

Needs review

A1C (current)5.9% prediabetes range

BMI34 obesity class I

Weight-related comorbiditiesHypertension, OSA

Prior GLP-1 historyNone

Clara: Your A1C is prediabetic, not T2D, so Ozempic and Mounjaro are off-label here. Your BMI and weight-related comorbidities make you a candidate for Wegovy or Zepbound (both on-label). I'll draft the chart summary for our physician to review.

Values and scenarios shown are illustrative examples only. All clinical assessments are individualized and reviewed by a licensed physician.

How it works

Connect your records. Clara reads the full picture. A physician signs off on every clinical action.

Connect your records

Clara auto-syncs your medical records from 150,000+ doctors' offices, hospitals, labs, and pharmacies: every prior lab, every prescription, every diagnosis. Wearable data syncs automatically on Standard and Concierge plans. Free to start, no credit card.

Clara checks candidacy, interactions, and dose

Before drafting any prescription, Clara reads your full chart: indication, contraindications, every drug and supplement on your list, and any prior trials of this medication. The interaction check runs against the full FDA label — not just the common flagged pairs.

Physician-reviewed Rx, then on-clock monitoring

Every prescription is reviewed and signed off by a licensed physician before it reaches your pharmacy. Clara then tracks the key monitoring labs on schedule — not at your next annual visit — and flags when dose adjustment or follow-up is warranted.

About GLP-1 receptor agonists

GLP-1 receptor agonists: what it treats, who it's for, and what Clara reads before prescribing.

FDA-approved indications

✓Ozempic (semaglutide): type 2 diabetes; CV risk reduction in T2D with established CVD; eGFR-decline reduction in T2D with CKD

✓Mounjaro (tirzepatide): type 2 diabetes

✓Wegovy (semaglutide): chronic weight management; MACE risk reduction in established CVD with obesity or overweight

✓Zepbound (tirzepatide): chronic weight management; moderate-to-severe OSA in adults with obesity

Who Clara evaluates for GLP-1 receptor agonists

✓Adults with type 2 diabetes above their A1C target, or with established CVD or CKD where MACE/renal risk reduction is a goal

✓Adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity

✓Patients already on a stable GLP-1 regimen who need dose review, refills, or a switch between agents based on response and tolerability

✗Patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2; patients in pregnancy

What Clara checks

Four things Clara reads before drafting — and keeps reading after.

🎯

Indication and candidacy

Clara reads your A1C, your BMI, your weight-related comorbidities, your CV history, and your prior anti-diabetic or weight-management treatments before matching you to a candidate GLP-1. It cross-checks personal and family history for MTC and MEN 2 — contraindications for every drug in this class.

⚠️

Drug and supplement interactions

All GLP-1s delay gastric emptying and can alter absorption of co-administered oral medications. Co-administration with insulin or sulfonylureas increases the risk of hypoglycemia. Tirzepatide (Mounjaro, Zepbound) specifically reduces the efficacy of oral contraceptives at initiation and dose escalation; the label recommends a non-oral backup for 4 weeks.

⚖️

Dose sizing

Every GLP-1 in this class follows a multi-week titration designed for tolerability, not weight or A1C effect. Ozempic and Mounjaro escalate over months for T2D; Wegovy and Zepbound escalate to higher maintenance doses for weight management. Clara reads your tolerance log against the calendar and the brand-specific dose schedule.¹

📅

On-schedule monitoring

A1C at 3-month intervals for T2D indications. Weight, BMI, and BP at 1- and 3-month intervals for weight indications. Renal function during dose escalation. Patients on insulin or sulfonylureas are monitored for hypoglycemia throughout titration.

Important safety information

GLP-1 receptor agonists (GLP-1s) is a prescription medication. The following is a summary of key safety information from the FDA-approved prescribing information. This is not a complete list — see the full prescribing information linked in the footer.

Boxed warning (entire class)

In rodent studies, GLP-1 receptor agonists in this class caused thyroid C-cell tumors. It is unknown whether they cause such tumors in humans. All four medications (Ozempic, Mounjaro, Wegovy, Zepbound) are contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Warnings

Acute pancreatitis (discontinue if suspected). Acute kidney injury (especially with dehydration from GI side effects). Hypoglycemia when used with insulin or sulfonylureas. Acute gallbladder disease. Diabetic retinopathy complications. Suicidal behavior and ideation (especially Wegovy/Zepbound). Reduced oral contraceptive efficacy with tirzepatide. Most common adverse reactions: nausea, vomiting, diarrhea, constipation, abdominal pain.

Monitoring requirements

A1C every 3 months for T2D indications. Weight, BMI, BP for weight indications. Renal function during dose escalation and with volume-depletion symptoms. Hypoglycemia screening in patients on concurrent insulin or sulfonylureas. Mental-health check-ins, especially with Wegovy and Zepbound.

Special populations

Pregnancy: discontinue at least 2 months before a planned pregnancy (Ozempic, Wegovy) or when pregnancy is recognized (Mounjaro, Zepbound). Lactation: limited data; consider risks and benefits. Pediatric: only Wegovy is approved for adolescents (≥12 years) with obesity. Geriatric: no dose adjustment, increased monitoring is reasonable. Renal/hepatic impairment: no dose adjustment required for any agent in the class.

Why Clara

How Clara manages GLP-1s differently.

	Clara	Cash-pay DTC GLP-1 telehealth	General telehealth	Your doctor
Cost to start	Free (records + chat)	Subscription required	Per-visit fee	$150+ copay
Monthly cost	From $25/mo · Standard $50/mo · HSA/FSA eligible	$199–$299/mo bundled cash-pay	Per-visit, varies	Per-visit copay
Matches on-label brand to your indication (T2D vs. weight vs. OSA)	✓ Reads chart, matches indication	Often single SKU regardless of indication	Limited triage	✓
Prescribes FDA-approved branded medication (not compounded)	✓ Branded	Often compounded semaglutide/tirzepatide	Varies	✓
Prescription may be covered by your insurance	✓	Cash-pay bundled	Varies	✓
Reads full chart and wearables	✓ 150,000+ sources	Intake questionnaire only	Self-uploaded only	Within a single practice
On-schedule A1C, weight, BP, and tolerance monitoring	✓	Patient-initiated	Patient-initiated	At next visit
Full primary care (beyond GLP-1 management)	✓	Single-vertical	Single-condition	✓

The AI difference

What an AI that reads your full chart makes possible in primary care.

A clinician in a 15-minute visit reads the last panel. Clara reads every result you've ever had drawn — every lab, every wearable reading, every medication change — and cross-references them in a single pass. That's not a time-management difference. It's a category-of-work difference. The AI handles the data; licensed physicians handle every clinical decision.

Reads your entire chart, every time

Clara auto-syncs from 150,000+ medical sources and reads every prior result, medication, and diagnosis together — not just the last visit's notes. Pattern-finding across years of data is what the AI is built for.

Continuous monitoring, not annual snapshots

Clara watches for drift between visits — a creeping lab value, a wearable trend, a new medication interaction — and surfaces it when it's actionable, not when you happen to schedule an appointment.

Physician review on every clinical action

Clara drafts; physicians decide. Every prescription and lab order is reviewed and signed by a licensed clinician before it reaches your pharmacy or lab. The AI handles intake, reasoning, and follow-up. The physician handles sign-off.

Common questions

GLP-1 receptor agonists with Clara: questions patients ask.

What does Clara cost?

Connecting your medical records and chatting with Clara is free. To access physician-reviewed prescriptions and lab orders, plans start at $50/month. Standard ($50/mo) includes 74 biomarker tests, wearable integration, and weekly record sync. Concierge ($150/mo) includes 108 biomarker tests and expanded panels. All plans are HSA/FSA eligible. Biomarker panels are included in the membership — not billed separately and not billed to insurance. Medications and ad-hoc lab orders are billed by your pharmacy or lab and may be covered by your insurance.

Can I use my insurance, HSA, or FSA?

Clara's membership is cash-pay and not billed through insurance, but every plan is HSA/FSA eligible. Prescriptions Clara's physicians write go to your pharmacy and may be covered by your plan like any other script — Clara prescribes FDA-approved branded and generic medications, not compounded formulations. Ad-hoc lab orders may also be covered by your insurance when applicable.

Is Clara a real medical practice?

Yes. Clara operates through affiliated professional corporations licensed in all 50 states. All diagnoses, prescriptions, and lab orders are reviewed and signed off by licensed physicians. Clara's AI handles intake, continuous monitoring, and clinical reasoning — the physician sign-off happens before any clinical action reaches you.

How is this different from my regular doctor?

A 15-minute annual visit can review your most recent results. Clara reads every lab you've had drawn, every medication you've been on, and every wearable data point in a single pass — and does it every time you interact, not just at annual visits. Your PCP remains the right choice for in-person exams, procedures, and anything Clara refers out. Clara fills the continuous monitoring gap between visits.

Is my data private?

Clara is HIPAA compliant. Your medical records and wearable data are used solely to personalize your care. They are not sold to third parties and are not used to train public AI models.

Which GLP-1 is right for me?

It depends on your diagnosis, your prior treatment history, and your insurance. For type 2 diabetes, Ozempic and Mounjaro are the on-label brands. For chronic weight management, Wegovy and Zepbound are on-label. For moderate-to-severe OSA in adults with obesity, Zepbound has a specific FDA indication. Clara reads your chart and your indication, and our physician matches you to the brand that fits both clinically and from an insurance perspective.

Does Clara prescribe compounded semaglutide or tirzepatide?

No. Clara's physicians prescribe FDA-approved branded GLP-1s (Ozempic, Mounjaro, Wegovy, Zepbound), not compounded formulations. Branded GLP-1s go through the standard pharmacy fill and may be covered by your insurance. Compounded semaglutide and tirzepatide are cash-pay products sold by some telehealth brands; Clara does not use them because the FDA has issued safety concerns about compounded GLP-1 formulations and because branded coverage through insurance is better long-term economics for most patients.

Can I switch between GLP-1s?

Yes, with physician oversight. Switching between agents in the class is common — most often for insurance coverage reasons or for tolerability or response. Clara reads your prior regimen, your response, and your side effects, drafts a switch plan including titration restart, and routes it to our physician. Direct dose-equivalence between agents is not assumed; the new agent starts at its label's initiation dose.